5 Einträge gefunden

1. Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.

   1. Wagenblast, Jens
   2. Hambek, Markus
   3. Baghi, Mehran
   4. Gstöttner, Wolfgang
   5. Strebhardt, Klaus
   6. Ackermann, Hanns
   7. Knecht, Rainald

   2008 - Forschungsinformationssystem des UKE
2. Demands on caring relatives of head and neck cancer patients.

   1. Baghi, Mehran
   2. Wagenblast, Jens
   3. Hambek, Markus
   4. Radeloff, Andreas
   5. Gstoettner, Wolfgang
   6. Scherzed, Agmal
   7. Spaenkuch, Birgit

   2007 - Forschungsinformationssystem des UKE
3. Reduction of cisplatin dosage by ZD 1839.

   1. Hambek, Markus
   2. Baghi, Mehran
   3. Strebhardt, Klaus
   4. Strebhard, Klaus
   5. Baumann, Helena
   6. Gstöttner, Wolfgang
   7. Knecht, Rainald

   2005 - Forschungsinformationssystem des UKE
4. Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN).

   1. Hambek, Markus
   2. Baghi, Mehran
   3. Baumaun, Helena
   4. Strebhardt, Klaus
   5. Strebhard, Klaus
   6. Adunka, Oliver
   7. Gstöttner, Wolfgang

   2005 - Forschungsinformationssystem des UKE
5. STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR.

   1. Hambek, Markus
   2. Baghi, Mehran
   3. Strebhardt, Klaus
   4. Strebhard, Klaus
   5. May, Angelika
   6. Adunka, Oliver
   7. Gstöttner, Wolfgang

   2004 - Forschungsinformationssystem des UKE